FDA Expands Label for Inclisiran to Include Adults With High

FDA Expands Label for Inclisiran to Include Adults With High LDL-C, Increased Risk of Heart Disease

The updated label for inclisiran (Leqvio) includes patients with comorbidities, such as hypertension and diabetes, who have yet to experience a cardiovascular event.

Related Keywords

Inclisiran Leqvio , Victor Bulto , Novartis , Novartis Innovative Medicines ,

© 2025 Vimarsana